Literature DB >> 30423420

Changes in motor cortical excitability in schizophrenia following transcranial direct current stimulation.

Pedro Caldana Gordon1, Leandro da Costa Lane Valiengo2, Vanessa Jesus Rodrigues de Paula3, Ricardo Galhardoni4, Ulf Ziemann5, Daniel Ciampi de Andrade6, Andre Russowsky Brunoni7.   

Abstract

Schizophrenia is a disorder associated with cortical inhibition deficits. Transcranial direct current stimulation (tDCS) induces changes in cortical excitability in healthy subjects and individuals with neuropsychiatric disorders depending on the stimulation parameters. Our aim was to investigate whether a previously published tDCS protocol associated with symptomatic improvement in schizophrenia would induce changes in motor cortical excitability, assessed by transcranial magnetic stimulation paradigms, i.e., short-interval intracortical inhibition (SICI) and intra-cortical facilitation (ICF). We assessed cortical excitability measurements in 48 subjects with schizophrenia before and after a single session of active tDCS (20 min, 2 mA, anode over left dorsolateral prefrontal cortex, cathode over left temporoparietal cortex) or sham. Those who received active tDCS had a significant increase of SICI in the left motor cortex compared to those who received sham stimulation (Cohen's d = 0.54, p = .019). No changes were observed for ICF. In addition, lower SICI was associated with higher age (β = -0.448, p < .01). Increase in intracortical inhibition may indicate a mechanism of action of tDCS in this population. Future studies should investigate whether this finding is a biomarker of treatment response for schizophrenia.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortical excitability; Negative symptoms; Schizophrenia; Transcranial direct current stimulation; Transcranial magnetic stimulation

Mesh:

Year:  2018        PMID: 30423420     DOI: 10.1016/j.pnpbp.2018.11.004

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

Review 1.  Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex for Treatment of Neuropsychiatric Disorders.

Authors:  Qing Li; Yu Fu; Chang Liu; Zhiqiang Meng
Journal:  Front Behav Neurosci       Date:  2022-05-25       Impact factor: 3.617

Review 2.  Beyond the target area: an integrative view of tDCS-induced motor cortex modulation in patients and athletes.

Authors:  Edgard Morya; Kátia Monte-Silva; Marom Bikson; Zeinab Esmaeilpour; Claudinei Eduardo Biazoli; Andre Fonseca; Tommaso Bocci; Faranak Farzan; Raaj Chatterjee; Jeffrey M Hausdorff; Daniel Gomes da Silva Machado; André Russowsky Brunoni; Eva Mezger; Luciane Aparecida Moscaleski; Rodrigo Pegado; João Ricardo Sato; Marcelo Salvador Caetano; Kátia Nunes Sá; Clarice Tanaka; Li Min Li; Abrahão Fontes Baptista; Alexandre Hideki Okano
Journal:  J Neuroeng Rehabil       Date:  2019-11-15       Impact factor: 4.262

3.  Combined effects of theta-burst stimulation with transcranial direct current stimulation of the prefrontal cortex: study protocol of a randomized, double-blinded, sham-controlled trial using 99mTc-ECD SPECT.

Authors:  Laís B Razza; Carlos A Buchpiguel; Stefanie De Smet; Izio Klein; Chris Baeken; Ricardo Galhardoni; Marie-Anne Vanderhasselt; André R Brunoni
Journal:  Trends Psychiatry Psychother       Date:  2021-02-24

4.  Treatment of depression in the elderly with repetitive transcranial magnetic stimulation using theta-burst stimulation: Study protocol for a randomized, double-blind, controlled trial.

Authors:  Leandro Valiengo; Bianca S Pinto; Kalian A P Marinho; Leonardo A Santos; Luara C Tort; Rafael G Benatti; Bruna B Teixeira; Cristiane S Miranda; Henriette B Cardeal; Paulo J C Suen; Julia C Loureiro; Renata A R Vaughan; Roberta A M P F Dini Mattar; Maíra Lessa; Pedro S Oliveira; Valquíria A Silva; Wagner Farid Gattaz; André R Brunoni; Orestes Vicente Forlenza
Journal:  Front Hum Neurosci       Date:  2022-08-31       Impact factor: 3.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.